瑞银重申康方生物买入评级 目标价一举升至197.5港元

Core Viewpoint - UBS reaffirms a buy rating for Kangfang Biopharma (09926.HK) and significantly raises the target price to HKD 197.5, highlighting the potential of its core product AK112 (ivonescimab) beyond non-small cell lung cancer (NSCLC) [1] Group 1: Product Potential - AK112 shows significant potential in indications beyond NSCLC, with six additional phase III clinical trials initiated covering areas such as cholangiocarcinoma, triple-negative breast cancer, and pancreatic cancer [1] - The breadth of indications for AK112 is noted to be the highest among similar drugs in the market [1] Group 2: Sales Growth and Market Impact - Following its inclusion in the national medical insurance directory in January, AK112 has experienced rapid sales growth [1] - The drug received approval for a new indication in NSCLC as a first-line treatment in May, which is expected to contribute additional revenue through negotiations in the medical insurance sector by 2025 [1] Group 3: Financial Projections - UBS has adjusted the peak sales estimates for AK112 in China and globally to USD 1.2 billion and USD 14.6 billion, respectively [1]